Facebook Linkedin Mail Twitter Youtube
Facebook Linkedin Mail Twitter Youtube

Tag: hATTR amyloidosis

Alnylam reports positive results from HELIOS-A phase III study of Vutrisiran...

Alnylam Pharmaceuticals has announced that the HELIOS-A phase III study of Vutrisiran, an investigational RNA interference (RNAi) therapeutic in development for the treatment of...
NeuroNews

Write to us
Editor: Jamie Bell [email protected]
Advertising: Abbie Richardson [email protected]


United Kingdom:

BIBA Medical, Europe
526 Fulham Road, Fulham, London, SW6 5NR
TEL: +44 (0)20 7736 8788
Email: [email protected]

United States:

BIBA Medical, North America
155 North Wacker Drive, Suite 4250, Chicago, IL 60606
TEL: +1 949 723 9309
Email: [email protected]

Terms and Conditions | Privacy Policy

Facebook Linkedin Mail Twitter Youtube